High- Versus Low-Density PASCAL Laser Treatment for Proliferative Diabetic Retinopathy
CENTRAL MACULAR THICKNESS AFTER HIGH- VERSUS LOW-DENSITY SINGLE-SESSION PATTERN SCAN LASER PANRETINAL PHOTOCOAGULATION IN PROLIFERATIVE DIABETIC RETINOPATHY: A RANDOMIZED NON-INFERIORITY TRIAL
This study aims to compare the effects of high-density and low-density single-session Pattern Scan Laser (PASCAL) panretinal photocoagulation (PRP) in patients with proliferative diabetic retinopathy (PDR).
Panretinal photocoagulation is a standard treatment for proliferative diabetic retinopathy. However, the number of laser spots applied during a single treatment session varies in clinical practice. This study will investigate whether applying a higher number of laser spots in one session is as safe and effective as applying a lower number of spots, particularly regarding changes in central macular thickness.
Eligible patients with proliferative diabetic retinopathy who have not previously received PRP will be randomly assigned to one of two groups. The low-density group will receive 2,200-3,000 laser spots, while the high-density group will receive 3,200-4,000 laser spots using the PASCAL laser system in a single session.
Central macular thickness will be measured using optical coherence tomography (OCT) before treatment and four weeks after treatment. The main purpose is to determine whether high-density PRP is not inferior to low-density PRP in terms of changes in central macular thickness. Visual acuity and treatment-related adverse effects will also be assessed.
The findings may help determine whether a higher number of laser spots can be safely delivered in a single PASCAL PRP session without causing an unacceptable increase in macular thickness.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
• Adults aged ≥ 18 years
- Type 1 or type 2 diabetes mellitus
- Treatment-naïve PDR with no clinically significant DME on OCT
- BCVA better than or equal to 6/60
- Baseline CMT <300 µm on Spectralis SD-OCT (central 1 mm ETDRS circle), with no intraretinal or subretinal fluid.
- Adequate pupil dilation and media clarity to perform OCT and laser photocoagulation
Exclusion Criteria:
- Other coexisting retinal eye diseases (ARMD, Retinal Vein Occlusion, Uveitis, tractional retinal detachments involving or threatening macula).
- Any previous retinal laser, anti-VEGF, or intravitreal/suprachoroidal steroid in the study eye.
- History of any intraocular surgery less than 6 months or Yag Capsulotomy less than 3 months in the study eye.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Group B
|
Participants will undergo single-session panretinal photocoagulation (PRP) using the PASCAL pattern scan laser system. A total of 2,200-3,000 laser spots will be applied to the peripheral retina. |
|
Active Comparator: Group A
|
Participants will undergo single-session panretinal photocoagulation (PRP) using the PASCAL pattern scan laser system. A total of 3,200-4,000 laser spots will be applied to the peripheral retina |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in Central Macular Thickness
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CHR-IREB-2026-0134
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.